Immunophotonics

Immunophotonics seeks cross-functional expertise in areas including ablation and immunotherapy and periodically posts information about job openings.

Dr. Von Hoff has conducted clinical trials on more than 200 antineoplastic and biologic agents. He served on President Bush’s National Cancer Advisory Board from 2004 to 2010 and was president of the American Association for Cancer Research.

Dr. Smoller is a General Partner at Cultivation Capital and previously served as Chief Scientific Officer of Sigma-Aldrich Corporation. He founded and exited life science companies, including ProteoPlex and Genome Systems Inc.

Dr. Naylor received his medical degree from Texas Tech University School of Medicine in 1981 and an internal medicine specialty certificate from the University of Alabama in 1984. He completed a tumor biology fellowship at MD Anderson Cancer Center in 1990.

Mr. Stark has more than 25 years of experience in the medical device sector, including nearly 20 years at AngioDynamics, where he served as Senior Vice President and General Manager of the Global Business Unit for Oncology.

Immunophotonics is a privately owned, clinical-stage biotech company developing treatments for solid-tumor cancers. Its first platform asset, IP-001, is being developed to turn tumor ablation into systemic cancer immunotherapy.

Immunophotonics lists its headquarters in St. Louis and a Swiss office operated by subsidiary IPS Biopharma AG in Bern, along with general inquiry and investment and partnering email addresses.

Immunophotonics' proprietary glycan polymer enhances antigen capture & immune processes, unlocking platform potential for immunotherapy.

The notice applies to SAKK 66/17, INJECTABL-1, INJECTABL-2 CRC, and INJECTABL-2 HCC, and states that Immunophotonics does not receive personally identifiable protected health information.

Immunophotonics raises $10 million in Series C funding to accelerate development of its lead asset, IP-001, in clinical trials. The company also appoints Robert H. Arch, Ph.D., as President and CEO to guide strategic growth initiatives. The financing supports advancing IP-001 toward potential therapeutic applications in oncology or immunology.

Sep 2026EIN PresswireNews article

Immunophotonics secures a key patent in China, strengthening its intellectual property protections for its core platform technology. The move expands the company’s global IP portfolio, covering critical markets. This development supports Immunophotonics’ efforts to safeguard its innovations in biophotonics and immunotherapy.

Jun 2026The National Law ReviewNews article

Immunophotonics completes enrollment for its **INJECTABL-1 Phase 1b/2a trial** testing **IP-001**, an immunostimulatory drug designed to enhance tumor destruction techniques. The study, involving **41 patients**, targets **colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma** across **France, Germany, and Switzerland**. The trial evaluates IP-001’s safety and efficacy in advanced solid tumors.

Jul 2025Yahoo FinanceNews article

Immunophotonics secures a U.S. patent (No. 11111316) for its lead drug candidate, a proprietary immune-activating carbohydrate polymer designed to treat metastatic cancers. The clinical-stage biopharmaceutical company develops novel therapies targeting cancer via immune activation. The patent covers its core proprietary technology in this therapeutic area.

Sep 2021BioSpaceNews article